Ambu (LSE:0MJF) - Stock Price, News & Analysis

0MJF Stock Overview

A medical technology company, develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. More details

0MJF fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 3.1% below our estimate of its fair value

Earnings are forecast to grow 28.05% per year

Earnings grew by 39.9% over the past year

Risk Analysis

Large one-off items impacting financial results

Ambu A/S Competitors

Smith & Nephew

LSE:SN.

UK£8.6b

NIOX Group

AIM:NIOX

UK£260.3m

EKF Diagnostics Holdings

AIM:EKF

UK£116.6m

ConvaTec Group

LSE:CTEC

UK£4.9b

Price History & Performance

Summary of all time highs, changes and price drops for Ambu
Historical stock prices
Current Share Price	DKK 114.85
52 Week High	DKK 154.65
52 Week Low	DKK 88.08
Beta	0.79
11 Month Change	-11.33%
3 Month Change	-25.17%
1 Year Change	26.25%
33 Year Change	-41.83%
5 Year Change	-1.84%
Change since IPO	1,620.60%

Recent updates

Shareholder Returns

	0MJF	GB Medical Equipment	GB Market
7D	-8.6%	7.7%	-0.4%
1Y	26.2%	-2.1%	5.6%

Return vs Industry: 0MJF exceeded the UK Medical Equipment industry which returned -2.1% over the past year.

Return vs Market: 0MJF exceeded the UK Market which returned 5.6% over the past year.

Price Volatility

Is 0MJF's price volatile compared to industry and market?
0MJF volatility
0MJF Average Weekly Movement	6.3%
Medical Equipment Industry Average Movement	6.1%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0MJF has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0MJF's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1937	5,196	Britt Jensen	www.ambu.com

Ambu A/S, a medical technology company, develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, and displaying units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products.

Ambu A/S Fundamentals Summary

How do Ambu's earnings and revenue compare to its market cap?
0MJF fundamental statistics
Market cap	DKK 30.50b
Earnings (TTM)	DKK 235.00m
Revenue (TTM)	DKK 5.39b

129.8x

P/E Ratio

5.7x

P/S Ratio

Is 0MJF overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0MJF income statement (TTM)
Revenue	DKK 5.39b
Cost of Revenue	DKK 2.19b
Gross Profit	DKK 3.20b
Other Expenses	DKK 2.97b
Earnings	DKK 235.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 30, 2025

Earnings per share (EPS)	0.88
Gross Margin	59.38%
Net Profit Margin	4.36%
Debt/Equity Ratio	0%

How did 0MJF perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

43%

Payout Ratio

Does 0MJF pay a reliable dividends?

See 0MJF dividend history and benchmarks

When do you need to buy 0MJF by to receive an upcoming dividend?
Ambu dividend dates
Ex Dividend Date	Dec 05 2024
Dividend Pay Date	Dec 09 2024
Days until Ex dividend	16 days
Days until Dividend pay date	20 days

Does 0MJF pay a reliable dividends?

See 0MJF dividend history and benchmarks

0MJF Stock Overview

Rewards

Risk Analysis

Ambu A/S Competitors

LSE:SN.

UK£8.6b

AIM:NIOX

UK£260.3m

AIM:EKF

UK£116.6m

LSE:CTEC

UK£4.9b

Price History & Performance

Recent News & Updates

Ambu A/S Proposes Dividend

Full year 2024 earnings released: EPS: kr.0.88 (vs kr.0.65 in FY 2023)

Ambu A/S, Annual General Meeting, Dec 03, 2025

Ambu A/S to Report Q1, 2025 Results on Jan 30, 2025

Third quarter 2024 earnings released: EPS: kr.0.50 (vs kr.0.19 in 3Q 2023)

Second quarter 2024 earnings released: EPS: kr.0.54 (vs kr.0.06 in 2Q 2023)

Recent updates

Ambu A/S Proposes Dividend

Full year 2024 earnings released: EPS: kr.0.88 (vs kr.0.65 in FY 2023)

Ambu A/S, Annual General Meeting, Dec 03, 2025

Ambu A/S to Report Q1, 2025 Results on Jan 30, 2025

Third quarter 2024 earnings released: EPS: kr.0.50 (vs kr.0.19 in 3Q 2023)

Second quarter 2024 earnings released: EPS: kr.0.54 (vs kr.0.06 in 2Q 2023)

First quarter 2024 earnings released

Ambu A/S Maintains Earnings Guidance for the Full-Year 2023/24

Ambu A/S Elects Shacey Petrovic as Vice Chair of Board of Directors

Ambu A/S Announces Henrik Ehlers Wulff Not to Run for Re-Election for Board of Directors

Ambu A/S Provides Earnings Guidance for the Full-Year 2023/24

Ambu A/S Appoints Henrik Skak Bender as Member of the Executive Management, Effective 1 January 2024

Ambu A/S Announces Chief Financial Officer Changes

Ambu A/S to Report Q2, 2024 Results on May 14, 2024

Ambu A/S Narrows Earnings Guidance for the Full-Year 2022/23

Third quarter 2023 earnings released

Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023

Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023

Second quarter 2023 earnings released

First quarter 2023 earnings released: EPS: kr.0.09 (vs kr.0.08 in 1Q 2022)

Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023

High number of new directors

Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023

Full year 2022 earnings released

Now 21% undervalued after recent price drop

Ambu A/S to Report Q3, 2023 Results on Aug 31, 2023

Now 23% undervalued after recent price drop

Ambu A/S(CPSE:AMBU B) dropped from FTSE All-World Index (USD)

Third quarter 2022 earnings released

Ambu A/S Reaffirms Earnings Guidance for the Full-Year 2021/2022

Investor sentiment deteriorated over the past week

Ambu A/S Revises Earnings Guidance for the Full-Year 2021/2022

Ambu Announces FDA Clearance of Fifth-Generation Single-Use Bronchoscope

Investor sentiment deteriorated over the past week

Ambu A/S Reaffirms Earnings Guidance for the Fiscal Year 2021/22

Second quarter 2022 earnings released

Less than half of directors are independent

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Ambu A/S Revises Revenue Guidance for the Fiscal 2022

Ambu Announces FDA Clearance of Single-Use Gastroscope and Next-Generation Display Unit

Upcoming dividend of kr.0.29 per share

Full year 2021 earnings released: EPS kr.0.98 (vs kr.0.98 in FY 2020)

Third quarter 2021 earnings released

Ambu A/S Revises Revenue Guidance for the Fiscal 2021

Second quarter 2021 earnings released

Ambu A/S Reaffirms Earnings Guidance for the Fiscal Year 2021

New 90-day high: kr.329

Ambu A/S has completed a Follow-on Equity Offering in the amount of DKK 1.2345 billion.

First quarter 2021 earnings released

Revenue beats expectations

New 90-day high: kr.301

Ambu A/S to Report Fiscal Year 2021 Results on Nov 09, 2021

New 90-day high: kr.215

Upcoming Dividend of kr.0.29 Per Share

New 90-day high: kr.211

Revenue misses expectations

Ambu A/S Announces Board Changes

Ambu A/S to Report Q2, 2021 Results on May 12, 2021

New 90-day low: kr.168